Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Valneva SE (VALN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.50-0.33 (-1.33%)
At close: 04:00PM EDT
Advertisement
Sign in to post a message.
  • s
    selmerstyle
    let’s talk lyme vaccine—when i fist started following this company covid wasn’t even a thing.

    how do we feel about the potential sales for that one…and anything else interesting in the pipeline (tired of the covid vaccine drama…need a new topic of conversation!)
  • J
    John
    losing the EU deal us very bad news.
  • D
    Dennis
    Duh, Lets go VALN and ingredient maker DVAX. Buh by Big Pharma shorties with their Toxic Vaccines

    Valneva says the European Medicines Agency accepted application for its COVID-19 vaccine

    U.S.-listed shares of Valneva SE jumped 11.5% in premarket trading on Thursday after the company said that the European Medicines Agency has accepted the application of its COVID-19 vaccine candidate. If the experimental shot receives a positive recommendation from the EMA's Committee for Human Medicinal Products, the company said it expects a decision in June. The European Commission then decides whether to authorize the vaccine. Valneva's vaccine is an inactivated, whole-virus shot that was te

    Sabin Vaccine Institute Receives up to $6.3 Million from CEPI for Dose-Optimizing COVID-19 Vaccine Clinical Trial
    GlobeNewswire
    COVID-19 Boosters: The Latest Advice
    Eat This, Not That!

    AdDaily Stock Buzz
    3 Superstar Stocks to Buy Right Now (Free Report)

    Discover 3 low-priced stocks to buy now, including our #1 growth stock for 2022. You'll find their names in this free Special Report
    GlobeNewswire•14 hours ago
    EMA Accepts Filing of Marketing Authorization Application for Valneva’s Inactivated COVID-19 Vaccine Candidate

    Saint Herblain (France), May 19, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirmed that the European Medicines Agency (“EMA”) has accepted the filing of a marketing authorization application (MAA) for Valneva’s inactivated, whole-virus COVID-19 vaccine candidate, VLA2001. Acceptance of the MAA means VLA2001 is advancing from the rolling review process and beginning the formal review process by the EMA’s Committee for Human Medicinal Products (CHM

    CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing
    CNW Group
    Sabin Vaccine Institute Receives up to $6.3 Million from CEPI for Dose-Optimizing COVID-19 Vaccine Clinical Trial
    GlobeNewswire
    Bullish
  • t
    timo
    Valneva beyond Covid
    1. Ixiaro & Dukoral - both marketed vaccines will gain momentum again as the travel market recovers. Before Covid they had combined sales of >100 m (US Army has a major multi-year contract)
    2. Chikungunya - most likely, a lot of militaries will buy this vaccine - peak sales can reach ~ 500 m. Not to forget, as Valneva will very likely be the first company to bring such a vaccine to the market, they will be eligible for a priority review voucher worth 80-100 m.
    3. Borellia - here the P 3 is expected to start in Q3 2022, peak sales clearly beyond 1 bn as this is a raising healthcare threat.
    4. Valneva will hopefully bring more assets into the clinic in the next 12-24 months
  • M
    Marcelino
    Zacks Rank & Stock to Consider

    Valnevacurrently carries a Zacks Rank #4 (Sell).
    Zacks Equity Research
    Tue, May 17, 2022, 2:10 PM
  • M
    Marcelino
    I was not acting dishonestly.
    I said strong sell at 16 euros.
    Not at 10 euros like Zack.
    He gave it a better rating before that.
    Only a deal that is now uncertain can't change a company's valuation that much.
  • J
    John
    You should be happy the stock is only down 20% premarket. That is a gift. Should be down 45 or 50%
  • g
    geragonew
    Guys Check it out oil PED. Earnings is after hour will be exploded.
  • M
    Matic
    In order to build your wealth you have to invest. Investing is the ability which allows you to put your money in vehicle that have the potential to earn strong rate of return.
  • m
    mark
    Does anyone know if VLA2001 that has been approved in UK is available there yet? I'd like to get the vaccine shot when I travel to London in a few weeks.
    Bullish
  • M
    Marcelino
    Money becomes more expensive.
    No profits, only share sales.
    No dividend.
    What is the point of buying this stock?
  • S
    Sean
    The current EU supply agreement is worth around 1 billion euro to Valneva...would that be correct? While their total market cap is only 1.5B euro. Looks like another covid wave could be incoming...if the EU approves this in April just as another wave hits then that could be extra bullish for price. Whatever about the long term success of this (and you could make a moderately bullish argument for that now that the jab has been validated by the UK health health authority) it could be worth throwing down at this price as a purely short term speculative play. I'm in (again), let's go!
  • M
    Marcelino
    I told you Strong sell ! last month, check it out
  • D
    Dennis
    VALN, is the best and safest Vaccine. No spike proteins and other graphic metal bio blades trash and nanobots etc. like MRNA and PFE Vaccines don't work and harm people.
  • D
    Dennis
    Marcello reply to bos own devious posts. look it up. this #$%$ has decent #s, potential, lots of cash and the drop in price from manipulation is staggering. when most bought this stock it had all ten anylist saying "Strong Buy"??. promoted by Robinhood to fleece young investors. I know this as I opened an account back then just to see how it works.This shorting should be investigated. Big Pharma Shorters?Any one interested?
  • J
    John
    think this will slowly creep back up. Europe has big deal with valneva. just dragging their feet a bit over approval. I Neen 15 to break even. would sell if it gets back to 19
  • M
    Marcelino
    I told you not to buy
  • S
    StratDD
    As announced on February 25, 2022, Valneva received a list of questions as part of the CHMP’s initial assessment to which it responded within two working days. Valneva has now received a small set of additional questions and is confident it will be able to respond to these in the coming days.

    With this additional round of questions and a tentative timetable also received from the EMA, and subject to the CHMP’s acceptance of Valneva’s responses, Valneva now anticipates receiving a positive CHMP recommendation for conditional approval of VLA2001 for primary immunization in adults 18 to 55 years of age in April 2022. Following such conditional approval, the Company would expect to start delivering planned doses of VLA2001 to European countries in the second quarter of 2022.

    https://finance.yahoo.com/news/valneva-provides-regulatory-covid-19-060000284.html
    Saint Herblain (France), March 11, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today provided an update on the regulatory review of its inactivated, COVID-19 vaccine candidate, VLA2001, by the Committee for Med
    Saint Herblain (France), March 11, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today provided an update on the regulatory review of its inactivated, COVID-19 vaccine candidate, VLA2001, by the Committee for Med
    finance.yahoo.com
  • B
    Bob
    Why the big rise in pre?
Advertisement
Advertisement